The MedsCheck program in Ontario has entered a period of intense scrutiny as newly released financial records and survey findings reveal significant billing increases and persistent pressure on pharmacists across major retail chains. The data shows a sharp escalation in MedsCheck revenues and highlights ongoing concerns surrounding corporate influence in pharmacy practice. These developments have renewed debate about the program’s design and the future of medication review services in the province.